Joan Teyra

Joan Teyra

Auto-generated profile, based on publicly available information

Joan Teyra

Icosagen Cell Factory OÜ Tartumaa Estonia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
JTJoan Teyra
Joan Teyra
AKAbdellali Kelil
Abdellali Kelil
SJShobhit Jain
Shobhit Jain
MHMohamed Helmy
Mohamed Helmy
RJRaghav Jajodia
Raghav Jajodia
SSSachdev Sidhu
Sachdev Sidhu
Many proteins involved in signal transduction contain peptide recognition modules (PRMs) that recognize short linear motifs (SLiMs) within their interaction partners. Here, we used large‐scale peptide‐phage display methods to derive optimal ligands for 163 unique PRMs representing 79 distinct structural families. We combined the new data with previous data that we collected for the large SH3, PDZ, and WW domain families to assemble a database containing 7,984 unique peptide ligands for 500 PRMs representing 82 structural families. For 74 PRMs, we acquired enough new data to map the specificity profiles in detail and derived position weight matrices and binding specificity logos based on multiple peptide ligands. These analyses showed that optimal peptide ligands resembled peptides observed in existing structures of PRM‐ligand complexes, indicating that a large majority of the phage‐derived peptides are likely to target natural peptide‐binding sites and could thus act as inhibitors of natural protein–protein interactions. The complete dataset has been assembled in an online database ( http://www.prm‐db.org ) that will enable many structural, functional, and biological studies of PRMs and SLiMs.

25 October 2019 in Protein Science
Verified
Journal Article
Closed access
PDF file
JTJoan Teyra
Joan Teyra
AEAndreas Ernst
Andreas Ernst
ASAlex Singer
Alex Singer
FSFrank Sicheri
Frank Sicheri
SSSachdev Sidhu
Sachdev Sidhu

22 December 2005 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
JBJaume Bonet
Jaume Bonet
GCGianluigi Caltabiano
Gianluigi Caltabiano
AKAbdul Kareem Khan
Abdul Kareem Khan
MJMichael A. Johnston
Michael A. Johnston
CCCarles Corbí
Carles Corbí
JVJordi Villà-freixa
Jordi Villà-freixa

29 January 2024 in Protein Science
Verified
Journal Article
Open access
TTTanner M. Tessier
Tanner M. Tessier
ACArvid Chowdhury
Arvid Chowdhury
ZSZane Stekel
Zane Stekel
JFJulia Fux
Julia Fux
MSMaria Augusta Sartori
Maria Augusta Sartori
Wei ZhangWei Zhang
Wei Zhang
Smurf1 and Smurf2 are two closely related member of the HECT (homologous to E6AP carboxy terminus) E3 ubiquitin ligase family and play important roles in the regulation of various cellular processes. Both were initially identified to regulate transforming growth factor‐β and bone morphogenetic protein signaling pathways through regulating Smad protein stability and are now implicated in various pathological processes. Generally, E3 ligases, of which over 800 exist in humans, are ideal targets for inhibition as they determine substrate specificity; however, there are few inhibitors with the ability to precisely target a particular E3 ligase of interest. In this work, we explored a panel of ubiquitin variants (UbVs) that were previously identified to bind Smurf1 or Smurf2. In vitro binding and ubiquitination assays identified a highly specific Smurf2 inhibitor, UbV S2.4, which was able to inhibit ligase activity with high potency in the low nanomolar range. Orthologous cellular assays further demonstrated high specificity of UbV S2.4 toward Smurf2 and no cross‐reactivity toward Smurf1. Structural analysis of UbV S2.4 in complex with Smurf2 revealed its mechanism of inhibition was through targeting the E2 binding site. In summary, we investigated several protein‐based inhibitors of Smurf1 and Smurf2 and identified a highly specific Smurf2 inhibitor that disrupts the E2–E3 protein interaction interface.

28 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AMA.J. Middleton
A.J. Middleton
JTJ. Teyra
J. Teyra
JZJ. Zhu
J. Zhu
SSSachdev Sidhu
Sachdev Sidhu
CDC.L. Day
C.L. Day
Summary: Transfer of ubiquitin to substrate proteins regulates most processes in eukaryotic cells. E2 enzymes are a central component of the ubiquitin machinery, and generally determine the type of ubiquitin signal generated and thus the ultimate fate of substrate proteins. The E2, Ube2k, specifically builds degradative ubiquitin chains on diverse substrates. Here we have identified protein-based reagents, called ubiquitin variants (UbVs), that bind tightly and specifically to Ube2k. Crystal structures reveal that the UbVs bind to the E2 enzyme at a hydrophobic cleft that is distinct from the active site and previously identified ubiquitin binding sites. We demonstrate that the UbVs are potent inhibitors of Ube2k and block both ubiquitin charging of the E2 enzyme, and E3-catalysed ubiquitin transfer. The binding site of the UbVs suggests they directly clash with the ubiquitin activating enzyme, while potentially disrupting interactions with E3 ligases via allosteric effects. Our data reveal the first protein-based inhibitors of Ube2k and unveil a hydrophobic groove that could be an effective target for inhibiting Ube2k and other E2 enzymes.